Chronic and progressive CNS diseases are caused by a synergistic action of genetic and environmental factors. They manifest themselves through a series of molecular events, often including self-reinforcing loops.
Every event is caused or paralleled by specific gene expression changes.
Biofrontera's approach is based on the analysis of these changes to provide understanding at the molecular level of the cascade of events preceding the appearance of overt symptoms. Our belief is that identifying key molecules that participate in early pathogenesis will point to novel drug targets, allowing the design of drugs to inhibit disease progression. To date, drug targets have been selected which are thought to play a key role in the development of pain. Compounds are tested in-house or through outside collaborations. Biofrontera Pharmaceuticals AG is interested in partnering opportunities preferentially with companies, which complement the discovery projects with suitable chemistry.